Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06082102 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv5
  2. Primary completion date: Aug 25, 2027 to Aug 31, 2028 Study sites: 20 to 19 · Interventions: Lenalidomide (Drug), Orelabrutinib (Drug), Orelabrutinib Placebo (Drug), Rituximab (Drug) to Lenalidomide (Drug), Orelabrutinib (Drug), Rituximab (Drug), Rituximab (Drug) · Eligibility criteria expanded, about 41 words · 1 morev4 Show 4 more changesShow less
    • Study sites: 20 to 19
    • Interventions: Lenalidomide (Drug), Orelabrutinib (Drug), Orelabrutinib Placebo (Drug), Rituximab (Drug) to Lenalidomide (Drug), Orelabrutinib (Drug), Rituximab (Drug), Rituximab (Drug)
    • Eligibility criteria expanded, about 41 words
    • Study title revised

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 11 to 20 Eligibility criteria shortened, about 19 wordsv3 Show 1 more changeShow less
    • Eligibility criteria shortened, about 19 words

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Oct 25, 2023 to Dec 19, 2023 · Site details revised at 11 of 11 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of Oct 25, 2023 to Dec 19, 2023
    • Site details revised at 11 of 11 sites
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Efficacy and Safety of Orelabrutinib Combined with Rituximab versus Lenalidomide Combined with Rituximab in Patients with Relapsed/Refractory Marginal Zone Lymphoma
Trial Details
NCT Number NCT06082102
Lead Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Conditions Relapsed/Refractory Marginal Zone Lymphoma
Enrollment 324 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov